Cure­Vac’s lead mR­NA pro­gram flunks a crit­i­cal PhI­Ib study, rais­ing ques­tions for high-pro­file biotech uni­corns

Cure­Vac’s lead­ing mR­NA pro­gram CV9104, a prostate can­cer vac­cine, has failed a crit­i­cal Phase IIb study. And that sting­ing set­back for the most ad­vanced clin­i­cal study in the field will raise fresh ques­tions about a com­plex new tech­nol­o­gy that has at­tract­ed bil­lions of dol­lars in in­vest­ment cash.

The Ger­man biotech re­port­ed that not on­ly did CV9104 fail the pri­ma­ry end­point on im­prov­ing over­all sur­vival, there was al­so no im­prove­ment on pro­gres­sion-free sur­vival over a place­bo.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN